ArticleClinical case reports2026
Successful Catheter-Directed Thrombolysis for a Patient With Intermediate-High-Risk Pulmonary Embolism: A Case Report.
Article in Clinical case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Successful Catheter-Directed Thrombolysis for a Patient With Intermediate-High-Risk Pulmonary Embolism: A Case Report.Clinical case reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acute pulmonary embolism (PE) is a prevalent cardiovascular condition with significant mortality and morbidity. Treatment strategies vary according to risk stratification. While anticoagulation is sufficient for low-risk patients, high-risk cases often necessitate systemic thrombolysis (ST) or surgical embolectomy. Catheter-directed therapy (CDT) has emerged as an alternative for high- and intermediate-high-risk patients, particularly when ST is contraindicated or poses a high bleeding risk. Through CDT, thrombolytic drugs are locally delivered straight into the pulmonary arteries. Despite promising outcomes in select cases, evidence for CDT remains inconclusive, reflected in its class-IIa recommendation in current guidelines. We describe a 44-year-old male who experienced sudden and worsening dyspnea over 5 days. The patient had a history of smoking, methadone addiction, and a recent motor vehicle accident, with a prior intracranial hemorrhage. Echocardiography revealed right ventricular dilation and systolic dysfunction, and computed tomography pulmonary angiography confirmed massive bilateral pulmonary artery thrombosis, while the patient's troponin level was 996 ng/L (reference < 2), categorizing the patient as intermediate-high risk. Due to contraindications to systemic thrombolysis and lack of response to anticoagulation, CDT was performed, resulting in rapid improvement in symptoms, oxygenation, and right ventricular function. The patient was discharged without complications. He was transitioned to oral anticoagulation and remained stable at three-month follow-up. This case highlights the potential of CDT as an effective and safe treatment for PE patients with intermediate-to-high risk who are not candidates for ST, a scenario with limited therapeutic options. CDT's routine use requires validation through additional studies and randomized trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.